In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Zepbound is an injectable prescription ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Weight loss drugs like Ozempic and Wegovy cost an average of $1,083 per month if you pay full price ... For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

To outperform the current options, these new treatments will need to deliver weight loss exceeding 20%, the average achieved with the highest dose of Zepbound. Novo Nordisk: The Danish pharma ...